Recce Shareholders Reject Remuneration Report In Second Strike, But Block Board Spill
RCE: $0.330 +0.00% · MC: $113M
Recce Pharmaceuticals shareholders delivered a second strike against the remuneration report, with more than a quarter of votes cast opposing it, but rejected the spill resolution. The AGM presentation said patient dosing is underway in Phase 3 trials of RECCE 327 Gel in Australia and Indonesia, with an independent committee expected to review Indonesian trial data as soon as mid-November; the company also reported an exclusive Australian and New Zealand licensing deal and a non-binding Middle East term sheet.

Comments